Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arvinas Inc.

    NASDAQ: ARVN · Real-Time Price · USD
    7.10
    -0.04 (-0.56%)
    At close: Aug 20, 2025, 3:59 PM
    7.10
    0.00%
    After-hours: Aug 20, 2025, 04:10 PM EDT
    -0.56%
    Bid 6.81
    Market Cap 521.26M
    Revenue (ttm) 372.8M
    Net Income (ttm) -72.6M
    EPS (ttm) -1.01
    PE Ratio (ttm) -7.03
    Forward PE -2.08
    Analyst Buy
    Ask 7.2
    Volume 867,223
    Avg. Volume (20D) 2,054,243
    Open 7.12
    Previous Close 7.14
    Day's Range 6.98 - 7.22
    52-Week Range 5.90 - 29.61
    Beta 2.23

    About ARVN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ARVN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ARVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Arvinas Inc. is scheduled to release its earnings on Oct 29, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 weeks ago
    -15.51%
    Arvinas shares are trading lower after the company... Unlock content with Pro Subscription
    2 months ago
    +8.82%
    Arvinas shares are trading higher after the company announced its submission of an NDA to the FDA for Vepdegestrant
    news image

    2 weeks ago · seekingalpha.com

    Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

    Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.

    news image

    2 weeks ago · zacks.com

    Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

    Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.

    news image

    2 months ago · zacks.com

    Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade

    The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positi...

    news image

    2 months ago · accessnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

    NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advise...

    news image

    2 months ago · reuters.com

    Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

    An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t...

    news image

    2 months ago · zacks.com

    Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?

    The consensus price target hints at a 94.9% upside potential for Arvinas (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

    news image

    2 months ago · businesswire.com

    Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN)

    NEW YORK--(BUSINESS WIRE)---- $ARVN #CLASSACTIONLAWSUIT--The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Arvinas, Inc. (“Arvinas” or the “...

    Add to Watchlist